neurologylive.com Breaking News Headlines Today | Ground News

neurologylive.com image

News from neurologylive.com

See all of neurologylive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 409 headlines written by neurologylive.com during the past 3 months.

Ground News rates neurologylive.com’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about neurologylive.com

Where is neurologylive.com located?neurologylive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top neurologylive.com News

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Edgewise Therapeutics (NASDAQ:EWTX)

100% Center coverage: 2 sources

On Monday, Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that causes progressive muscle weakness. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read: Edgewise Therapeutics Stock S…See the Story

Dementia risk linked to three personality traits new study suggests

Dementia · Santa Monica

Dementia risk linked to three personality traits new study suggests

100% Right coverage: 1 sources

US-based researchers at thinktank RAND found 12 factors that influence the risk of developing the condition - three of which are to do with your personalitySee the Story

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Parkinson's Disease

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease

Roche Shares Promising Phase IIb PADOVA Study Results for Prasinezumab in Early-Stage Parkinson’s Disease (IN BRIEF) Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression narrowly missed statistical significance, promising efficacy trends were observed, particularly among participants receiving …See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc